AI Model Predicts Inpatient Surgical Discharges
The machine-learning model could be used to increase timeliness of discharges, investigators suggested.
Related Articles
FDA Approves Ustekinumab (STELARA) Biosimilar for Chronic Inflammatory Diseases
The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Stronger Safety Considerations Needed for Lumateprone Use, Especially for Women
Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.
Short-Term Surge in Air Pollution May Trigger Schizophrenia Episodes
A short-term rise in air pollution levels between neighboring days was significantly linked to an increased risk of schizophrenia hospitalizations in China.
Zobair Younossi, MD, MPH: Resmetirom’s Impact on Health-Related Quality of Life in MASH
Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.
Study Finds Adrenaline Auto-Injectors Mostly Ineffective Against Fatal Anaphylaxis
During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such…
Topiramate, Pregabalin Reduce Headache Frequency, Intensity in Pediatric Migraine
A meta-analysis revealed taking pregabalin with supplement vitamin D reduced migraine frequency in children by 88%
Balancing the Benefits and Risks of Xanomeline and Trospium Chloride Capsules
In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.
Highly Beneficial Antipsychotics Underutilized in People With Schizophrenia
Second-generation long-acting injectables were particularly underutilized, and especially among older patients.
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Xanomeline trospium chloride offers a new pathway in schizophrenia treatment, improving cognitive symptoms without D2 receptor-related side effects like tardive dyskinesia.
First Melanoma History is Risk Factor for Subsequent Diagnoses Regardless of Race
This analysis indicates that patients with a history of a first melanoma are at risk for subsequent development of melanoma regardless of their race or…